Page 190 - GHES-2-4

Global Health Economics and
Sustainability
Addressing response to new drug indications

NICE. (2024). NICE Disappointed Companies Unwilling to deruxtecan. Global Health Economics and Sustainability,
Offer Fair Price to Make Enhertu Available for Advanced 2(1):1889.
Breast Cancer. NICE. Available from: https://www.nice. https://doi.org/10.36922/ghes.1889
org.uk/news/articles/nice-disappointed-that-companies-
unwilling-to-offer-fair-price-to-the-nhs-to-make-enhertu- Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Caro, J.J.,
available [Last accessed on 2024 Jul 30]. Lee, K.M., Minchin, M., et al. (2014). Budget impact
analysis-principles of good practice: Report of the ISPOR
Riveros, B.S., Cavalcanti, M.G., Leonart, L.P., Rosim, M.P.,
Almeida, A.B., & Licursi, C.A. (2024). Budgetary impact 2012 budget impact analysis good practice II task force.
of new label indications after initial drug registration in Value in Health, 17(1):5-14.
Brazil: A case study of pembrolizumab and trastuzumab https://doi.org/10.1016/j.jval.2013.08.2291

Volume 2 Issue 4 (2024) 3 https://doi.org/10.36922/ghes.4439